Last reviewed · How we verify
levodopa MR
At a glance
| Generic name | levodopa MR |
|---|---|
| Also known as | levodopa MR/carbidopa/ODM-104 |
| Sponsor | Orion Corporation, Orion Pharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study (PHASE2)
- Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease (EARLY_PHASE1)
- An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas
- 18F-DOPA-PET/MRI Scan in Imaging Elderly Patients With Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma During Planning for a Short Course of Proton Beam Radiation Therapy (PHASE2)
- Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- levodopa MR CI brief — competitive landscape report
- levodopa MR updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI